Demineralized Bone Matrix Market, By Product Type (Putty, Gel, Paste, Strips/Sheets, and Others), By Tissue Source (Allograft, and Xenograft), By Application (Spinal Fusion, Trauma, Foot and Ankle, Dental, and Other Applications), By End User (Hospitals, Orthopedic Clinics, Academic and Research Institutes, Ambulatory Surgical Centers, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Aug 2024

Code : CMI4550

Pages :172

Formats :

Excel and PDF

Industry : Medical Devices

Market Challenge - High cost of bone grafting procedures

One of the key challenges for the global demineralized bone matrix market is the high cost associated with bone grafting procedures. Bone grafting is an expensive orthopedic procedure, and the costs vary depending on the type, extent of graft needed, and procedures used. Typically, an autogenously bone graft procedure can cost anywhere between US$ 10,000 and US$ 20,000. Allograft procedures are slightly cheaper but can still range from US$ 5,000 to US$ 15,000. The high costs pose affordability issues especially in developing regions where healthcare budgets are limited. This challenge restricts the ability of surgeons to opt for bone graft procedures for certain non-life threatening conditions like bone fractures and injuries where other alternative treatments may be opted. Addressing the challenge of costs would be important for unlocking the market potential in developing regions.

Market Opportunity- New Product Innovations and Launches

The global demineralized bone matrix market is expected to witness new opportunities arising from constant new product innovations and launches. Vendors in the market are investing heavily in R&D to develop advanced bone graft solutions with improved handling properties, faster incorporation time, and better clinical outcomes. Many companies are focusing on developing bone graft substitutes that can mimic the structure and properties of natural bones. Launch of synthetic bone graft materials, bone morphogenic protein formulations, and bone graft composite products are expanding the product pipeline. Such new product innovations are helping address the various unmet needs of orthopedic surgeons and patients better. They are also diversifying the portfolio of treatment options available to the clinicians. This is expected to drive the overall market revenues during the forecast period.